Clinical Trial Update: Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 [Phase 3]

View source ↗

Summary

Phase 3 trial exploring ocrelizumab's effect on brain innate immune microglial activation in multiple sclerosis using PET-MRI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapse

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Multiple Sclerosis, Relapse | Phase 3 | Status: UNKNOWN